spacer
home > pmps > autumn 2018 > postponement potential
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Postponement Potential

Postponement packaging, or late-stage customisation, is the supply chain practice of keeping a product in a standard format for as long as possible, only making it market- or customer-specific when demand arises. To date, the adoption of postponement across the pharmaceutical supply chain has been limited. However, given the potential cost, resource, and time savings associated with postponement, companies can benefit from the significant advantages this strategy has to offer.

Postponement Principle

The fundamental principle of postponement is to keep products market-agnostic to enable drug manufacturers to react quickly to changes in demand. It offers businesses a strategic solution to respond to specific market needs, optimising their inventory management and simplifying their supply chain.

Rather than finalising a product and moving it to the relevant country for storage, it can be partially prepared and then stored in a centrally located warehouse. Then, when stock is needed, it can be tailored according to marketspecific requirements and shipped within very short timeframes – sometimes, in a matter of hours.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dexter Tjoa is the Director of Corporate Strategy at Tjoapack. He is responsible for devising, implementing, and evaluating the midto long-term strategies of the company and the services it offers, as well as overseeing the commercial department within Tjoapack. Dexter holds a BSc in mathematics from the University of London, UK, and an MSc in mathematics and computer science from the University of Oxford, UK, and has previously worked in the technology sector.
spacer
Dexter Tjoa
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing and customer service.
More info >>

White Papers
 
Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement